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A B S T R A C T
Background: Olfactory impairment increases the risk of developing neurodegenerative diseases in patients with
idiopathic REM sleep behavior disorder (IRBD). Knowing the test properties of distinct olfactory measures could
contribute to their selection for clinical or research purposes.
Objective: To compare the accuracy in distinguishing IRBD patients from controls with the University of
Pennsylvania Smell Identification Test (UPSIT-40) and Sniffin' Sticks Extended test, and to assess the gray-matter
volume correlates of these tests.
Method: Twenty-one patients with IRBD and 27 healthy controls were assessed using both olfactory tests.
Independent logistic regressions were computed with diagnosis as a dependent variable and olfactory measures
as predictive variables. Receiver operating characteristic curves were computed for each olfactory subtest.
Diagnostic accuracy for IRBD was calculated according to the resulting optimal cut-off score. Structural MRI
data, acquired with a 3T scanner, were analyzed with voxel-based morphometry.
Results: Patients differed from controls in all olfactory measures. The Sniffin-Identification correctly classified
89.1% of cases; the UPSIT-40, 85.4%; the Sniffin-Discrimination, 82.6%; the Sniffin-Total, 81.8%; and the
Sniffin-Threshold, 77.3%. Respective AUROC, optimal cut-off, sensitivity, and specificity for each test were:
0.902, ≤26, 85.7%, and 85.2% for the UPSIT-40; 0.884, ≤29, 89.5%, and 76.0% for the Sniffin-Total; 0.922,
≤11, 90.5%, and 88.0% for the Sniffin-Identification; 0.739, ≤4, 73.7%, and 76.0% for the Sniffin-Threshold;
and 0.838, ≤11, 85.7%, and 76.0% for the Sniffin-Discrimination. UPSIT-40 scores correlated with gray-matter
volumes in orbitofrontal regions in anosmic patients.
Conclusions: UPSIT-40 and Sniffin' Identification showed similar discrimination accuracy, but only the UPSIT-40
showed structural correlates (p≤ .05 FDR-corrected).
1. Introduction
Rapid eye movement (REM) sleep behavior disorder (RBD) is a
parasomnia characterized by abnormal motor and vocal behaviors as-
sociated with unpleasant dreams and increased electromyographic ac-
tivity during REM sleep [1]. The idiopathic form of RBD (IRBD) is di-
agnosed when RBD symptomatology occurs in the absence of associated
comorbidities or known causing factors. Patients with IRBD are at high
risk of eventually developing a neurodegenerative disease, such as
dementia with Lewy bodies (DLB), Parkinson's disease (PD), or multiple
system atrophy [2,3]. In this setting, IRBD has been described as the
strongest and most specific clinical predictor of neurodegenerative
disease available [4]. Therefore, there is a growing interest in finding
clinical biomarkers of neurodegeneration in this prodromal disorder.
Since olfactory loss has also been recognized as a premotor
symptom of PD [5,6], it has been widely studied as a possible biomarker
of neurodegeneration in IRBD [7]. In this sense, olfactory impairment in
RBD has been reported in 35.7–97.0% of patients compared with
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2.5–16.6% of healthy control subjects [7]. Furthermore, previous works
have found RBD patients with olfactory dysfunction to have an in-
creased short-term risk of developing manifested PD and DLB [3,8].
Therefore, improving the accuracy of olfactory clinical testing in IRBD
could help identify patients at a higher risk of conversion to a neuro-
degenerative disease, and thus define target populations for disease-
prevention trials.
The University of Pennsylvania Smell Identification Test (UPSIT-40)
and the Sniffin’ Stick test are the most frequently used tests to evaluate
olfaction worldwide. Both tests have been traditionally used as diag-
nostic complementary tools in PD [9,10] and their accuracy for this
disease is high [11–14]. Furthermore, methods have been proposed to
convert between UPSIT-40 and Sniffin’ Stick test scores with meta-
analytic purposes [15]. Nevertheless, as far as we know, no previous
published works have compared in the same study neither the accuracy
of UPSIT-40 and Sniffin’ Stick tests in distinguishing IRBD patients from
controls, nor the neuroanatomical correlates of these tests in IRBD
patients.
In the current work, we aimed to compare the accuracy and brain
correlates of two smell tests in IRBD patients and to describe its optimal
cut-off scores for this disorder. It was hypothesized that: (1) IRBD pa-
tients will have worse performance than healthy controls in all olfac-
tory measures; (2) Sensitivity and specificity of smell identification tests
for IRBD will be comparable for the tests assessed in manifested PD; and




Twenty-one patients with IRBD were recruited from the multi-
disciplinary Sleep Unit at Hospital Clinic, Barcelona. Diagnosis of RBD
required a history of dream-enacting behaviors, video-polysomno-
graphic demonstration of REM sleep without atonia, associated with
abnormal behaviors, absence of motor and cognitive complaints at the
time of the recruitment, unremarkable neurological examination,
normal brain magnetic resonance imaging and no temporal association
between the estimated onset of RBD and the introduction or withdrawal
of a medication [16,17]. Twenty-seven healthy subjects (HC) without
cognitive, motor, or sleep complaints were recruited from the Institut
de l’Envelliment (Barcelona, Spain).
Exclusion criteria consisted of [1]: Presence of psychiatric and/or
neurologic comorbidity [2], MMSE score< 25 [3], claustrophobia [4],
MRI artifacts [5], pathological MRI findings other than mild white
matter hyperintensities, and [6] exclusion of HC with evidence of a
clinical history suggestive of abnormal sleep behaviors and cognitive
impairment. Specific exclusion criteria for the olfaction test were: (1)
history of nasal bone fracture, (2) diagnosis of rhinitis or nasal polyps,
and (3) upper respiratory tract infections in the two weeks prior to
testing.
The study was approved by the Ethics Committee of the University
of Barcelona (IRB00003099) and Hospital Clinic (HCB/2014/0224). All
subjects provided written informed consent.
2.2. Olfactory and clinical assessment
Olfaction was assessed using the Spanish version of the UPSIT-40
[9] and the Sniffin’ Sticks Extended Test [18]. The UPSIT-40 is a
standardized multiple-choice scratch-and-sniff test consisting of four
test booklets with 10 items each. In accordance with normative in-
structions, subjects scratch the impregnated area and are asked to select
one of four possible answers for each item.
The Sniffin’ Sticks Extended Test (www.burghart-mt.de) consists of
three subtests [1]: the Threshold test (Sniffin-Thr) used to ascertain the
patient's olfactory threshold. It has 48 Sniffin’ Sticks (32 blanks and 16
dilutions of n-butanol) [2]; the Discrimination test (Sniffin-D), where
the patient must differentiate between smells with varying degrees of
similarity. It consists of 48 Sniffin’ Sticks (48 Sniffin’ Sticks= 16 pairs
of odorants each with one individual smell); and [3] the Identification
test (Sniffin-I) that consists of 16 Sniffin’ Sticks with everyday smells
which the patients have to identify using a selection card containing
four choices. The results of all subtests are added up to get the total
score (Sniffin-Total).
Presence of motor symptoms was evaluated using the International
Parkinson and Movement Disorders Society Unified Parkinson's Disease
Rating Scale motor section (MDS-UPDRS-III). Neurological examination
based on the MDS-UPDRS-III frequently disclosed mild parkinsonian
signs, that were, however, not sufficient to diagnose Parkinsonism ac-
cording to standard criteria [19].
The Beck Depression Inventory II (BDI), the Starkstein's Apathy
Scale (AS), and the Neuropsychiatric Inventory (NPI) were adminis-
tered to all subjects to explore the presence of psychiatric symptoms.
Finally, the Innsbruck REM Sleep Behavior Disorder Inventory (RBD-I)
was used to study the presence RBD-like symptomatology in both pa-
tients and controls for comparisons.
2.3. MRI acquisition and analyses
MRI data were acquired with a 3T scanner (MAGNETOM Trio,
Siemens, Germany). The scanning protocol included high-resolution 3-
dimensional T1-weighted images acquired in the sagittal plane
(TR=2300ms, TE=2.98ms, TI= 900ms, 240 slices,
FOV=256mm; 1mm isotropic voxel) and an axial FLAIR sequence
(TR=9000ms, TE=96ms).
2.4. Definition of regions of interest
A mask that defined the olfactory system was created including the
amygdalae; hippocampi; thalami; insular cortices; parahippocampal
gyri; superior frontal gyrus, orbital part; middle frontal gyrus, orbital
part; gyrus rectus; olfactory cortex; and the limbic subregion of the
striatum (including the nucleus accumbens and the ventral portion of
the caudate nucleus and putamen bilaterally). The Automated
Anatomical Labeling atlas was used to create the corresponding masks,
except the limbic striatum mask, which was obtained from the Oxford-
GSK-Imanova striatal connectivity atlas (available in FSL).
2.5. Gray matter volume analysis: voxel-based morphometry
Structural data was analyzed with FSL-VBM (http://fsl.fmrib.ox.ac.
uk/fsl/fslwiki/FSLVBM), an optimized voxel-based morphometry
(VBM) protocol [20] carried out with FSL tools [21]. First, structural
images were brain-extracted and gray-matter-segmented before being
registered to the MNI 152 standard space using non-linear registration.
The resulting images were averaged to create a study-specific template,
to which native gray matter images were non-linearly re-registered.
Second, all native gray matter images were non-linearly registered to
this study-specific template, resampled to a voxel size of 2x2x2 mm3,
and modulated to correct for local expansion or contraction due to the
non-linear component of the spatial transformation. A mask encom-
passing the structures of interest (see Definition of Regions of interests)
was created to define a search volume for subsequent statistical testing.
A voxelwise general linear model with non-parametric permutation
testing (5,000 permutations) was used alongside threshold-free cluster
enhancement for statistical inference. False-discovery rate (FDR) cor-
rection was applied for multiple comparisons correction. Statistical
significance was established at FDR-corrected p-values (q-values) <
0.05.
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2.6. Statistical analyses of non-MRI analyses
Statistical analyses of demographic, clinical, and olfactory data
were carried out using the statistical package SPSS-24 (2016; Armonk,
NY: IBM Corp.). The Mann-Whitney U test was used to assess group
differences between IRBD and healthy subjects in clinical and olfactory
continuous variables, and Pearson's chi-squared test was applied to
assess group differences in categorical variables. Correlations between
olfactory measures and clinical scores in IRBD patients were analyzed
using Spearman's rho correlation. Finally, stepwise independent binary
logistic regressions were computed introducing the diagnosis (either
healthy subject or IRBD) as a dependent variable and the olfactory
measures as predictive variables. The Bonferroni method was used to
correct for multiple comparisons.
A receiver operating characteristic (ROC) curve was computed for
each olfactory measure. RStudio (2015; available online at: www.
rstudio.com) was used to calculate statistical differences of area under
the curve (AUC) values from ROC (AUROC) analysis. Sensitivity, spe-
cificity, diagnostic accuracy, positive predictive value, and negative
predictive value for IRBD were calculated according to the resulting
optimal cut-off. In this setting, altered test performances were con-
sidered as positive findings, whereas correct performance defined ne-
gatives. True positives (TP) were defined as the number of IRBD pa-
tients with altered performance in a certain test; true negatives (TN) as
the number of HC with correct performance; false positives (FP) were
calculated as the number of HC with altered performance; finally, false
negatives (FN) were described as the number of IRBD patients who had
scores greater than the optimal cut-off. The following diagnostic mea-
sures were calculated: (1) Sensitivity, defined as the probability of
testing positive when IRBD is present: TP/(TP + FN); (2) Specificity,
defined as the probability of testing negative when IRBD is absent: TN/
(FP + TN); (3) Positive predictive value (PPV), calculated as the per-
centage of subjects with a positive test who actually have IRBD: TP/
(TP + FP); (4) negative predictive value (NPV), defined as the per-
centage of subjects with a negative test who do not have IRBD: TN/
(TN + FN); finally, (5) overall diagnostic accuracy was defined as the
proportion of correctly classified subjects among all subjects:
(TP + TN)/(TP + TN + FP + FN).
3. Results
3.1. Demographic and clinical characteristics
No significant differences between groups were found in age, years
of education, sex, BDI, and AS. Intergroup differences were found in
NPI (U=418.000; p < .001) and RBD-I scores (U=466.000;
p < .001) (Table 1).
3.2. Comparison between healthy subjects and IRBD patients in olfactory
performance
After adjusting for age, years of education, and sex, intergroup
differences were found in UPSIT-40 total score (U=64.000;
p < .001), Sniffin-D (U=82.000; P < .001), Sniffin-I (U=48.000;
p < .001) and Sniffin-Total (U=65.000; p < .001) scores (Table 1).
Following the normative cut-offs of each test, the percentage of HC
and IRBD patients identified as normosmic, hyposmic, and anosmic was
calculated (Supplementary material 1).
3.3. Correlation with clinical measures
No correlations were found in the IRBD group between olfactory
measures and age, years of education, disease duration, NPI, AS, and
BDI. The RBD-I was the only clinical measure that correlated with ol-
factory measures in IRBD patients, specifically with Sniffin-I scores
(r=−.550; P= .012).
3.4. Discrimination between HC and IRBD by means of olfactory testing
Stepwise independent logistic regressions were performed to as-
certain the effects of each single test on IRBD identification. The logistic
regression model was statistically significant for UPSIT-40
(X2= 29.563; P=< .001), the Sniffin-I (X2= 34.326; P < .001), the
Sniffin-Thr (X2= 5.312; P= .021), the Sniffin-D (X2=19.842;
P=< .001), and the Sniffin-Total (X2= 23.755; P < .001). The
Sniffin-I model explained 70.3% of the variance in IRBD and correctly
classified 89.1% of cases; the UPSIT-40 model explained 61.6% of the
variance and correctly classified 85.4%; the Sniffin-Total model ex-
plained 56.0% of the variance and correctly classified 81.8%; the
Sniffin-D model explained 46.8% of the variance and correctly classi-
fied 82.6%; finally, the Sniffin-Thr model explained 15.3% and cor-
rectly classified 77.3% of the cases (Table 2).
3.5. Optimal cut-off scores and their accuracy measures for the olfactory
tests in IRBD
The ROC curve showed that the optimal cut-off score for the UPSIT-
40 (AUROC=.902) was ≤26 with a sensitivity of 85.7% and a speci-
ficity of 85.2%. For the Sniffin-Total (AUROC=.884) the optimal cut-
off was ≤29 with 89.5% sensitivity and 76.0% specificity. For the
Sniffin’ subtests the respective optimal cut-off scores, sensitivity, and
specificity were: ≤11, 90.5%, and 88.0% for the Sniffin-I
(AUROC=.922); ≤4, 73.7%, and 76.0% for the Sniffin-Thr
(AUROC=.739); and ≤11, 85.7%, and 76.0% for the Sniffin-D
(AUROC=.838) (Fig. 1, Supplementary material 2 and 3). AUROC
values comparisons only showed significant differences between UPSIT-
40 and Sniffin-Thr (t= 2.082; P= .037).
3.6. MRI correlates of olfactory test
In IRBD patients with anosmia, the UPSIT-40 test correlated posi-
tively with a cluster involving the right medial frontal cortex, right
frontal orbital cortex, and left subcallosal cortex (2222 voxels; co-
ordinates of cluster maximum: X=12, Y=40, Z=−22) (Fig. 2). No
significant correlations were found either for Sniffin’ total score or for
Sniffin’ subtests.
4. Discussion
To our knowledge, this is the first work comparing the UPSIT-40
and the Sniffin’ Sticks test in the same sample of IRBD patients. In line
with evidence from the literature, IRBD patients showed impaired ol-
factory identification and discrimination when compared with matched
healthy subjects. We found that olfactory identification measures are
the best smell predictor of IRBD; in particular, Sniffin’ Identification
scores had the highest classification accuracy. On the other hand, worse
UPSIT-40 performance was related to gray matter reduction in orbito-
frontal cortex regions in anosmic IRBD patients, whereas Sniffin’ subt-
ests did not show significant structural brain correlates.
We found that IRBD patients had impaired performance in both
UPSIT-40 and Sniffin’ Sticks total scores, as well as in Sniffin’
Identification and Sniffin’ Discrimination subtests. Previous studies
have reported impaired smell identification in IRBD patients in com-
parison with HC using the Sniffin’ Identification [3,22,23], the UPSIT
short version (B-SIT-12) [24,25], the UPSIT-40 [26,27], the Sniffin’
Sticks screening 12 test [28], and the Odor Stick Identification Test for
Japanese [23]. Smell discrimination impairment has been also reported
[3,23], as well as smell threshold increment [3,23,27]. As expected,
these results highlight the presence of olfactory impairment in IRBD
patients assessed with different smell tests. Otherwise, for clinical
purposes it may be interesting to study the ability of tests to identify
olfactory deficits in IRBD patients.
Our results showed that smell identification was the olfactory
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domain that better discriminated IRBD patients; specifically, Sniffin’
Identification had the greatest accuracy classification for IRBD (89.1%),
followed by the UPSIT-40 (85.4%). Although, Sniffin’ Identification
(AUROC=.922) had slightly higher AUC values than UPSIT-40
(AUCROC=.902), these differences did not reach statistical sig-
nificance. In the same line, Sniffin’ Identification was the only olfactory
subtest that correlated with the RBD-I scale. A previous longitudinal
study found Sniffin’ Identification subtest had a diagnostic accuracy of
82.4% in predicting IRBD conversion to a Lewy body disease.
Interestingly, in this same study, those subjects who converted had a
baseline olfactory performance similar to that described in PD, whereas
non-converters had significantly better smell function [3]. Similarly, a
5-year longitudinal study found that, compared with disease-free pa-
tients, IRBD subjects who eventually developed PD or DLB had lower
scores at baseline in the UPSIT-40 [8]. In the same line, a recent work
with a large multicenter cohort of IRBD patients found that the rate of
neurodegenerative phenoconversion was significantly increased with
olfactory deficit (hazard ratio= 2.62) [29]. Taken together, these re-
sults suggested that olfactory tests may be useful tools for dis-
criminating HC from IRBD. In addition, previous longitudinal studies
also showed the relevance of olfactory measures for predicting which
IRBD patients are more likely to convert earlier to PD and DLB. Iden-
tifying these patients during the prodromal phase will conceivably help
to select subjects in the design of future disease-modifying trials.
As far as we know, this is the first study providing diagnostic ac-
curacy data and optimal cut-off scores for both UPSIT-40 and Sniffin’
Sticks tests for discriminating IRBD patients from healthy subjects. As
suggested by the logistic regression, taking an IRBD optimal cut-off
revealed that smell identification tests had the greatest sensitivity and
specificity (respectively, 85.7% and 85.2% for the UPSIT-40; and 90.5%
and 88.0% for the Sniffin’ Identification). In line with our results, data
from a previous work with Japanese IRBD patients reflected Sniffin’
Table 1
Inter-group comparisons of demographic, clinical, and olfactory measures.
Demographic and clinical characteristics
HC (n=27) IRBD (n= 21) T stat/p
Age 66.4(9.9) 71.8(7.9) 69.500/.074
Years of education 12.2(4.3) 11.7(4.9) 262.500/.661
Sex (male/female) 13/14 15/6 2.634/.105
NPI 1.9(2.5) 6.3(5.8) 418.000/< .001
BDI 5.1(4.7) 6.8(4.9) 298.500/.265
AS 8.9(5.3) 10.8(5.5) 312.000/.155
RBD-I 0.2(0.1) 0.6(0.2) 466.000/< .001
RBD duration – 4.62 (3.3) –
MDS-UPDRS-III – 2.5 (1.9) –
Olfactory test
adjusted Z raw score adjusted Z raw score
Sniffin Discrimination 0.1(0.9) 12.3(2.0) −1.6(1.6) 8.3(3.2) 82.000/< .001
Sniffin Identification 0.1(0.8) 13.1(1.6) −2.4(1.6) 8.0(2.8) 48.000/< .001
Sniffin Threshold −0.2(0.9) 5.7(2.0) −0.9(1.5) 3.8(3.1) 134.000/.014
Sniffin Total 0.0(0.9) 31.1(4.5) −2.1(1.6) 20.7(7.0) 65.000/< .001
UPSIT-40 0.0(0.9) 30.6(4.6) −2.1(1.4) 19.7(6.6) 64.000/< .001
Abbreviations: AS, Starkstein's Apathy Scale; BDI, Beck Depression Inventory II; HC, healthy controls; IRBD, idiopathic form of REM-sleep behavior disorder; NPI,
Neuropsychiatric Inventory; RBD-I, Innsbruck REM Sleep Behavior Disorder Inventory; Sniffin, Bughart Sniffin’ Sticks extended test; MDS-UPDRS-III, Movement
Disorders Society Unified Parkinson's Disease Rating Scale motor section; UPSIT-40, University of Pennsylvania Smell Identification Test. Measures for demographic
and clinical data are presented as mean scores (SD). For the olfactory test, measures are presented as mean scores (SD) of the Z scores corrected for age, years of
education, and sex; and mean (SD) of the raw scores. Group differences were tested using Mann-Whitney's U test or Chi-square test. For the olfactory data group
differences in adjusted Z were tested using Mann-Whitney's U test. In bold those results that survive Bonferroni correction for multiple comparisons.
Table 2
Logistic regression analyses.
B SE Wald/P value Exp (B) Nagelkerke R2 PAC (HC/IRBD) X2/p value
UPSIT-40
UPSIT-40 -.306 .080 14.630/< .001 .736 .616 85.4 (88.9/81.0) 29.563/< .001
Constant 7.636 2.114 13.048/< .001 2071.755
Sniffin Identification
Sniffin-I -.857 .232 13.688/< .001 .425 .703 89.1 (92.0/85.7) 34.326/< .001
Constant 9.202 2.628 12.260/< .001 9920.754
Sniffin Threshold
Sniffin-Thr -.289 .136 4.544/.033 .749 .153 77.3 (84.0/68.4) 5.312/.021
Constant 1.081 .690 2.453/.117 2.948
Sniffin Discrimination
Sniffin-D -.533 .157 11.526/.001 .587 .468 82.6 (88.0/76.2) 19.842 < .001
Constant 5.479 1.746 9.849/.002 239.535
Sniffin Total
Sniffin-Total -.263 .073 13.120/< .001 .769 .560 81.8 (88.0/73.7) 23.755/< .001
Constant 6.708 2.007 11.170/.001 818.587
Abbreviations: HC, healthy controls, IRBD, idiopathic form of REM-sleep behavior disorder; PAC, percentage accuracy in classification for the whole sample, for HC
and for IRBD patients; SE, standard error; Sniffin, Bughart Sniffin’ Sticks extended test; Sniffin-D, Sniffin Discrimination; Sniffin-I, Sniffin Identification; Sniffin-Total,
Sniffin Total score; Sniffin-Thr, Sniffin Threshold; UPSIT-40, University of Pennsylvania Smell Identification Test. Independent binary logistic regression with
stepwise method was computed introducing group membership (HC vs. IRBD) as a dependent variable and the olfactory measures as predictive variables.
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Identification was the Sniffin’ subtest with greatest sensitivity [23].
From a clinical point of view, both UPSIT-40 and Sniffin identification
are useful, but Sniffin’ identification is less time consuming.
The voxel-based-morphometry analysis showed that, in anosmic
IRBD patients, worse performance in the UPSIT-40 was associated with
gray matter reduction in orbitofrontal regions with a right hemisphere
predominance. Our results are in line with a previous work in healthy
subjects that found a positive correlation between gray matter volume
in right orbitofrontal and olfactory performance [30], highlighting the
important role of this region in olfactory function. Using cortical
thickness analysis, previous studies with IRBD reported lower perfor-
mance on the UPSIT-40 to be correlated with bilateral orbitofrontal, left
precentral [31] and occipital thinning [32]. Another study, assessing
brain perfusion in IRBD, showed that performance in the UPSIT 12-item
version was related to regional cerebral blood low reduction in the
anterior parahippocampal gyri [33]. Regarding results in PD samples,
and in line with our results, a study conducted with early PD patients
showed that atrophy in the orbitofrontal cortex was associated with
olfactory dysfunction [34]. On the whole, evidence suggest a potential
role of orbitofrontal cortex not only in healthy subjects, but also in
IRBD and PD patients. We can speculate that orbitofrontal involvement
in anosmic IRBD could be reflecting that patients with worse odor
identification may be those that eventually evolve to PD.
The strengths of this work are the inclusion of two smell assessment
tools commonly used worldwide, the study of olfactory test structural
correlates in IRBD patients, and the exclusion of potential causes of
secondary smell loss in our sample. Main limitation is a relatively small
sample, especially to detect MRI correlates for the Sniffin’ subtests.
In summary, we found that both, UPSIT-40 and Sniffin’
Identification, had high accuracy to detect olfactory dysfunction in
IRBD patients. Moreover, we found that gray matter reduction in or-
bitofrontal regions in anosmic IRBD may contribute to the degree of
impairment in UPSIT-40 performance.
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